WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 556063
CAS#: 1262770-73-9 (free base)
Description: KHS-101 is a selective inducer of neuronal differentiation. KHS101 induces neuronal differentiation in cultured hippocampal neural progenitor cells (NPCs) by interacting with TACC3 (EC50 ~1 μM). KHS101 disrupts energy metabolism in human glioblastoma cells and reduces tumor growth in mice. KHS101 promoted tumor cell death in diverse GBM cell models. KHS101 exerted cytotoxic effects by disrupting the mitochondrial chaperone heat shock protein family D member 1 (HSPD1). In GBM cells, KHS101 promoted aggregation of proteins regulating mitochondrial integrity and energy metabolism.
MedKoo Cat#: 556063
Name: KHS-101 free base
CAS#: 1262770-73-9 (free base)
Chemical Formula: C18H21N5S
Exact Mass: 339.1518
Molecular Weight: 339.461
Elemental Analysis: C, 63.69; H, 6.24; N, 20.63; S, 9.44
Related CAS #: 1784282-12-7 (HCl) 1262770-73-9 (free base)
Synonym: KHS-101; KHS 101; KHS101;
IUPAC/Chemical Name: N4-isobutyl-N2-((2-phenylthiazol-4-yl)methyl)pyrimidine-2,4-diamine
InChi Key: DGRJOOOHPBSAHD-UHFFFAOYSA-N
InChi Code: InChI=1S/C18H21N5S/c1-13(2)10-20-16-8-9-19-18(23-16)21-11-15-12-24-17(22-15)14-6-4-3-5-7-14/h3-9,12-13H,10-11H2,1-2H3,(H2,19,20,21,23)
SMILES Code: CC(C)CNC1=NC(NCC2=CSC(C3=CC=CC=C3)=N2)=NC=C1
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: To be determined
Shelf Life: >2 years if stored properly
Drug Formulation: To be determined
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 339.461 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Parma B, Ramesh V, Gollavilli PN, Siddiqui A, Pinna L, Schwab A, Marschall S, Zhang S, Pilarsky C, Napoli F, Volante M, Urbanczyk S, Mielenz D, Schrøder HD, Stemmler M, Wurdak H, Ceppi P. Metabolic impairment of non-small cell lung cancers by mitochondrial HSPD1 targeting. J Exp Clin Cancer Res. 2021 Aug 7;40(1):248. doi: 10.1186/s13046-021-02049-8. PMID: 34364401; PMCID: PMC8348813.
2: Polson ES, Kuchler VB, Abbosh C, Ross EM, Mathew RK, Beard HA, da Silva B, Holding AN, Ballereau S, Chuntharpursat-Bon E, Williams J, Griffiths HBS, Shao H, Patel A, Davies AJ, Droop A, Chumas P, Short SC, Lorger M, Gestwicki JE, Roberts LD, Bon RS, Allison SJ, Zhu S, Markowetz F, Wurdak H. KHS101 disrupts energy metabolism in human glioblastoma cells and reduces tumor growth in mice. Sci Transl Med. 2018 Aug 15;10(454):eaar2718. doi: 10.1126/scitranslmed.aar2718. PMID: 30111643.
3: Campo L, Breuer EK. Inhibition of TACC3 by a small molecule inhibitor in breast cancer. Biochem Biophys Res Commun. 2018 Apr 15;498(4):1085-1092. doi: 10.1016/j.bbrc.2018.03.125. Epub 2018 Mar 19. PMID: 29555478.
4: Tamura R, Yoshihara K, Saito T, Ishimura R, Martínez-Ledesma JE, Xin H, Ishiguro T, Mori Y, Yamawaki K, Suda K, Sato S, Itamochi H, Motoyama T, Aoki Y, Okuda S, Casingal CR, Nakaoka H, Inoue I, Verhaak RGW, Komatsu M, Enomoto T. Novel therapeutic strategy for cervical cancer harboring FGFR3-TACC3 fusions. Oncogenesis. 2018 Jan 23;7(1):4. doi: 10.1038/s41389-017-0018-2. PMID: 29358619; PMCID: PMC5833787.
5: Zhang Y, Kibaly C, Xu C, Loh HH, Law PY. Temporal effect of manipulating NeuroD1 expression with the synthetic small molecule KHS101 on morphine contextual memory. Neuropharmacology. 2017 Nov;126:58-69. doi: 10.1016/j.neuropharm.2017.08.030. Epub 2017 Aug 24. PMID: 28842345.
6: Zhou DS, Wang HB, Zhou ZG, Zhang YJ, Zhong Q, Xu L, Huang YH, Yeung SC, Chen MS, Zeng MS. TACC3 promotes stemness and is a potential therapeutic target in hepatocellular carcinoma. Oncotarget. 2015 Sep 15;6(27):24163-77. doi: 10.18632/oncotarget.4643. PMID: 26219398; PMCID: PMC4695177.
7: Guo Y, Partch CL, Key J, Card PB, Pashkov V, Patel A, Bruick RK, Wurdak H, Gardner KH. Regulating the ARNT/TACC3 axis: multiple approaches to manipulating protein/protein interactions with small molecules. ACS Chem Biol. 2013 Mar 15;8(3):626-35. doi: 10.1021/cb300604u. Epub 2012 Dec 26. PMID: 23240775; PMCID: PMC3600089.
8: Wurdak H, Zhu S, Min KH, Aimone L, Lairson LL, Watson J, Chopiuk G, Demas J, Charette B, Halder R, Weerapana E, Cravatt BF, Cline HT, Peters EC, Zhang J, Walker JR, Wu C, Chang J, Tuntland T, Cho CY, Schultz PG. A small molecule accelerates neuronal differentiation in the adult rat. Proc Natl Acad Sci U S A. 2010 Sep 21;107(38):16542-7. doi: 10.1073/pnas.1010300107. Epub 2010 Sep 7. Erratum in: Proc Natl Acad Sci U S A. 2010 Dec 21;107(51):22360. Halder, Rajkumar [added]. PMID: 20823227; PMCID: PMC2944756.
